AnGes

AnGes

AnGes was founded in 1999 out of Osaka University, commercializing hepatocyte growth factor (HGF) gene therapy research by Professor Ryuichi Morishita. The firm went public on the Tokyo Stock Exchange Mothers market in 2002, making it one of the earliest publicly listed biotech ventures built around a single gene therapy platform. Ei Yamada, who took the CEO role after extensive senior leadership at pharmaceutical and medical device companies, now helms operations from the firm's dual headquarters in Ibaraki and Tokyo's Minato ward. AnGes's core business is developing and commercializing DNA plasmid-based therapies. The firm's flagship product, Collategene (beperminogene perplasmid), gained conditional and time-limited approval from Japan's Ministry of Health, Labour and Welfare in 2019 for critical limb ischemia — marking the country's first commercial gene therapy. AnGes built a direct sales force in Japan targeting vascular surgeons and stocked the drug through a limited network of hospital pharmacies, a strategy that makes the firm a rare example of a biotech retaining end-to-end commercialization capability for a gene therapy. Beyond HGF, the firm expanded its pipeline to include a Tie2 agonist for acute respiratory distress syndrome and pursued an intradermal DNA vaccine against SARS-CoV-2. The COVID-19 program ultimately transferred to a carve-out entity, EmendoBio, listed on the Tokyo Stock Exchange Growth market. Geographically, AnGes's operations are concentrated in Japan but supported earlier research collaborations with university hospitals in North America and Europe. As of its latest filings, the firm operates with a lean workforce dedicated to clinical development, regulatory affairs, and pharmaceutical sales. September 2021: AnGes announced it would spin off its COVID-19 DNA vaccine business into EmendoBio, completing the listing in December 2021 (per the firm's official communications). The creation of EmendoBio illustrated AnGes's willingness to use corporate restructuring rather than pure licensing to finance and focus pipeline assets. The group structure now separates the steady-state Collategene commercial entity from riskier pandemic-response development, allowing each vehicle to pursue distinct capital allocation strategies. AnGes's structural edge lies in owning the entire value chain for Japan's gene therapy pioneer market — regulatory dossier, hospital distribution logistics, and physician outreach — skills rare among discovery-stage biotechs. The firm's public listing, uncommon for a niche single-asset biotech, subjects it to quarterly disclosure that provides an unusual level of transparency into how an early gene therapy commercializes in a single-payer health system.